[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
IDEAYA Biosciences, Inc. Common Stock (IDYA)
GSK terminates collaboration agreement with IDEAYA Biosciences for two clinical programs, impacting Werner Helicase and Pol Theta. Despite this, IDEAYA's stock nears a 52-week high, buoyed by positive analyst sentiment and IND clearance for IDE034.
About IDEAYA Biosciences, Inc. Common Stock
IDEAYA Biosciences, Inc. is a biotechnology company focused on developing cancer therapies.
IDEAYA Biosciences, Inc. Common Stock uses the ticker $IDYA for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- IDEAYA Biosciences, Inc. Common Stock (IDYA) social dominance hit XXXXXX which is XXX% higher than it's daily average.
- IDEAYA Biosciences, Inc. Common Stock (IDYA) trading volume is up XXXXX% from the previous week.
- IDEAYA Biosciences, Inc. Common Stock (IDYA) social dominance is up 1080.65% from the previous X months.
- IDEAYA Biosciences, Inc. Common Stock (IDYA) engagements is up XXXXX% from the previous week.
- IDEAYA Biosciences, Inc. Common Stock (IDYA) posts created is up XXXXX% from the previous week.
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock price is nearing its 52-week high, supported by positive analyst ratings and favorable social sentiment, including a 'Buy' rating and a price target of $XX from Truist Securities. The recent IND clearance for IDE034 further bolsters investor confidence and indicates strong upward momentum.
24-Hour: XXXX% 7-Day: -XXXX% 30-Day: XXXX%
1-Year High: $XX on 2025-12-04
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
IDEAYA Biosciences, Inc. Common Stock (IDYA) is currently AltRank #878 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXXXX +74
X Month: XXXXX +310
X Months: XXXXX +468
X Year: XXXXX +611
1-Year High: XXXXX on 2025-08-29
1-Year Low: XX on 2025-01-11
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -XX
X Month: XX -XX
X Months: XX +9
X Year: XX -XX
1-Year High: XX on 2025-07-24
1-Year Low: X on 2025-06-11
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
X Week: XXXXXX +52%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX +56%
X Year: XXXXXXXXX +69%
1-Year High: XXXXXX on 2025-09-08
1-Year Low: XXX on 2025-05-10
Engagements by network (24h): Reddit: XX X: XXXXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +2.80%
X Months: XXXXX +82%
X Year: XXXXX +125%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-01-27
Mentions by network (24h): Reddit: XX X: XXX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning IDEAYA Biosciences, Inc. Common Stock (IDYA) in the last XX hours which is down XX% from XXX in the previous XX hours
Daily Average: XX
X Week: XXX +7.40%
X Month: XXX +11%
X Months: XXXXX +196%
X Year: XXXXX +124%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-06-01
The most influential creators that mention IDEAYA Biosciences, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BiopharmIQ | X | XXXXXX | X | XXXXX |
| @AponiaAnalytics | X | XXXXX | X | XXX |
| @semodough | X | XXXXXX | X | XXX |
| @BuyTheUgly | X | XX | X | XX |
| @SteveDJacobs | X | XXXXX | X | XX |
| @bioinvestor24 | X | XXXXX | X | XX |
| @seedytx19 | X | XXXXX | X | XX |
| @ParadiseTraderr | X | XXX | X | XX |
| @bryan_plat47867 | X | XXX | X | XX |
| @JoseRestonVA | XX | XXXXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% +6%
1-Year High: XXX% on 2025-03-17
1-Year Low: XX% on 2025-02-04
Most Supportive Themes:
- Pipeline Potential: (45%) The company's drug pipeline, including its Uveal Melanoma drug and DLL3 programs, is expected to have a significant market impact.
- Analyst Ratings: (25%) Positive analyst ratings from Barclays and Citizens, with price targets of $XX and $XX respectively, indicate confidence in the stock's future performance.
Most Critical Themes:
- Biotech Volatility: (10%) The inherent volatility of the biotech sector requires careful monitoring of overall market trends.
Social Dominance: XXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.02%
X Month: XXXXX% +0.024%
X Months: XXXXX% +0.034%
X Year: XXXXX% +0.025%
1-Year High: XXXXX% on 2024-12-31
1-Year Low: XXXXXX% on 2025-06-01
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-11-26
1-Year Low: XXXXXXX% on 2025-03-19
Market Cap: $XXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$7.10%
X Month: $XXXXXXXXXXXXX +$4.90%
X Months: $XXXXXXXXXXXXX +$52%
X Year: $XXXXXXXXXXXXX +$25%
1-Year High: $XXXXXXXXXXXXX on 2025-12-04
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08
Top IDEAYA Biosciences, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"🦐🥃💫🧛 For those asking how I find my trading ideas: I follow Prof. @zmmm__o's free daily alerts. His analysis as a finance professor is next level. #SP500 #NXXTFedBoost $BULL #IREN🐘 $IHS #BearMarket🦝 $INDB #FinancialAdvisors🔮 $ICON #GrowthStock🌞 $IDYA"
X Link @SomerT46649 2025-12-11T21:23Z X followers, XX engagements
"$IDYA -XXXX% today as IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma More Info:"
X Link @OzmosiHealth 2025-12-11T17:37Z 3015 followers, XX engagements
"IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma #biotech #news"
X Link @sfbionetwork 2025-12-11T13:06Z 2051 followers, XX engagements
"IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma"
Reddit Link @Quantisnow 2025-12-11T11:27Z X followers, X engagements